{
    "organizations": [],
    "uuid": "7265a88e0348164624f7b6545879440266f675b2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-resverlogix-medison-pharma-ltd-ann/brief-resverlogix-medison-pharma-ltd-announce-strategic-licensing-agreement-idUSFWN1P30QV",
    "ord_in_thread": 0,
    "title": "BRIEF-Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Resverlogix Corp:\n* RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT\n* RESVERLOGIX CORP - ‍UNDER TERMS OF AGREEMENT, MEDISON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET APABETALONE IN ISRAEL​\n* RESVERLOGIX CORP - CO IS ELIGIBLE TO RECEIVE FROM MEDISON, ASCENDING DOUBLE DIGIT ROYALTIES BASED ON FUTURE NET SALES OF PRODUCT IN REGION\n* RESVERLOGIX CORP - ENTERED LICENSING AGREEMENT WITH MEDISON PHARMA FOR CO‘S LEAD THERAPEUTIC CANDIDATE, APABETALONE IN ISRAEL AND PALESTINE AUTHORITY\n* RESVERLOGIX CORP - MEDISON WILL BE RESPONSIBLE FOR ALL REGULATORY, SALES AND MARKETING COSTS FOR APABETALONE IN ISRAEL REGION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T22:13:00.000+02:00",
    "crawled": "2018-01-09T17:09:25.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "resverlogix",
        "corp",
        "resverlogix",
        "medison",
        "pharma",
        "announce",
        "strategic",
        "licensing",
        "agreement",
        "resverlogix",
        "corp",
        "term",
        "agreement",
        "medison",
        "exclusive",
        "right",
        "distribute",
        "market",
        "apabetalone",
        "resverlogix",
        "corp",
        "co",
        "eligible",
        "receive",
        "medison",
        "ascending",
        "double",
        "digit",
        "royalty",
        "based",
        "future",
        "net",
        "sale",
        "product",
        "region",
        "resverlogix",
        "corp",
        "entered",
        "licensing",
        "agreement",
        "medison",
        "pharma",
        "co",
        "lead",
        "therapeutic",
        "candidate",
        "apabetalone",
        "israel",
        "palestine",
        "authority",
        "resverlogix",
        "corp",
        "medison",
        "responsible",
        "regulatory",
        "sale",
        "marketing",
        "cost",
        "apabetalone",
        "israel",
        "region",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}